帕博西利布
细胞周期蛋白依赖激酶
细胞周期蛋白依赖激酶6
化学
视网膜母细胞瘤蛋白
细胞周期蛋白依赖激酶复合物
细胞周期蛋白依赖激酶4
细胞周期蛋白D
激酶
癌症研究
细胞周期蛋白
细胞周期
细胞生物学
生物化学
癌症
乳腺癌
细胞周期蛋白依赖激酶2
生物
蛋白激酶A
细胞
遗传学
转移性乳腺癌
作者
Keelan Z. Guiley,Jack W. Stevenson,Kevin Lou,Krister J. Barkovich,Vishnu Kumarasamy,Tilini U. Wijeratne,Katharine L. Bunch,Sarvind Tripathi,Erik S. Knudsen,Agnieszka K. Witkiewicz,Kevan M. Shokat,Seth M. Rubin
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2019-12-13
卷期号:366 (6471)
被引量:167
标识
DOI:10.1126/science.aaw2106
摘要
The p27 protein is a canonical negative regulator of cell proliferation and acts primarily by inhibiting cyclin-dependent kinases (CDKs). Under some circumstances, p27 is associated with active CDK4, but no mechanism for activation has been described. We found that p27, when phosphorylated by tyrosine kinases, allosterically activated CDK4 in complex with cyclin D1 (CDK4-CycD1). Structural and biochemical data revealed that binding of phosphorylated p27 (phosp27) to CDK4 altered the kinase adenosine triphosphate site to promote phosphorylation of the retinoblastoma tumor suppressor protein (Rb) and other substrates. Surprisingly, purified and endogenous phosp27-CDK4-CycD1 complexes were insensitive to the CDK4-targeting drug palbociclib. Palbociclib instead primarily targeted monomeric CDK4 and CDK6 (CDK4/6) in breast tumor cells. Our data characterize phosp27-CDK4-CycD1 as an active Rb kinase that is refractory to clinically relevant CDK4/6 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI